MLXIPL and cancer: Overall, these data demonstrated that, while sorafenib induced persistent OXPHOS inhibition eliciting a Warburg shift to glycolysis, pharmacological inhibition of ChREBP by SBI-993 can acutely curtail this shift, thereby reducing cancer cell survival by restoring sensitivity to sorafenib treatment (Supplementary Fig. 16f).